Cytecare appoints Dr Vikram Kekatpure as Senior Consultant – Head & Neck Surgical Oncology

Cytecare is looking forward to leverage his experience and years of practice in bringing innovation and strengthening the patient-centric approach of the hospital

Bengaluru-based Cytecare Cancer Hospitals has appointed of Dr Vikram Kekatpure as Senior Consultant Head & Neck Surgical Oncology. Dr. Kekatpure is a renowned oncologist with over 14 years of experience in clinical care, teaching and research. His key specialisation includes oral cancer, thyroid diseases, laryngeal cancer, skull base tumour, microvascular reconstruction and advanced head and neck tumour.

Suresh Ramu, CEO and Co Founder, Cytecare Hospitals, said “We are delighted to have Dr Kekatpure on board as Consultant Head & Neck Surgical Oncology. Dr Kekatpure brings in great value to Cytecare with his specialised and research-based approach. Cytecare is looking forward to leverage his experience and years of practice in bringing innovation and strengthening the patient-centric approach of the hospital.”

Prior to joining Cytecare, Dr Kekatpure worked as a Senior Consultant – Head and Neck Surgical Oncology and Reconstructive Surgery, at NH-Mazumdar-Shaw Medical Center, Bangalore.

Speaking on his appointment, Dr Kekatpure said, “I am happy to be a part of the Cytecare family and I believe that working with this hospital will help me leverage my experience to push Cytecare’s endeavour in creating a more patient-centric cancer care system.”

Dr Kekatpure has received several awards including the noteworthy Scholar-in-Training award from the AACR and from FHNO for his research paper. Some of his papers provide insights on issues like oral cavity and reconstruction options, laryngeal cancers, mid face reconstruction, head and neck reconstruction etc. He is an active member of various influential medical societies nationally and internationally like the Foundation for Head and Neck Oncology India (FHNO), Indian Association of Cancer Research, American Association of Cancer Research (AACR), AO foundation and the Head and Neck Cooperative Oncology Group.